Compare ENHA & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENHA | AARD |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.5M | 97.4M |
| IPO Year | 2025 | 2025 |
| Metric | ENHA | AARD |
|---|---|---|
| Price | $7.10 | $1.00 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 11 |
| Target Price | ★ $22.33 | $4.00 |
| AVG Volume (30 Days) | 211.6K | ★ 1.2M |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.11 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $118.94 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $0.93 |
| 52 Week High | $14.09 | $16.60 |
| Indicator | ENHA | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 57.45 | 29.19 |
| Support Level | $6.30 | N/A |
| Resistance Level | $14.09 | $5.78 |
| Average True Range (ATR) | 1.29 | 0.20 |
| MACD | -0.25 | 0.10 |
| Stochastic Oscillator | 32.89 | 11.82 |
Enhanced Group Inc develops and sells sports and performance-related products intended for use by athletes and consumers. Its offerings focus on products associated with physical performance, health, and recovery. Its two principal offerings include: (i) the Enhanced Games, a live, multi-sport competition platform designed to showcase both "Enhanced" and "Non-Enhanced" athletes pursuing world-record performances under medically supervised conditions; and (ii) Live Enhanced, a direct-to-consumer digital and clinician-guided wellness platform offering evidence-based protocols, supplements, and coaching for consumers seeking to improve health, longevity, and well-being. The majority of the company's revenue is derived from products associated with physical performance, health, and recovery.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.